Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer now expands to six marketed products and several other assets in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.
Bayer's Oncology Pipeline
Oncology Pipeline Website
The oncology pipeline website provides awareness and education on Bayer’s diverse oncology pipeline for healthcare professionals globally. The website features Bayer’s pipeline compounds at various stages of clinical development and across a range of research areas. It also provides clinical trial information and educational content like mechanism of disease videos and downloadable pipeline resources.
Oncology Pipeline Brochure
The oncology franchise at Bayer includes oncology products and investigational compounds at various stages of clinical development. The oncology pipeline brochure provides an overview of Bayer’s investigational compounds, areas of research and tumour types of interest in oncology clinical development.
Educational Resources Microsite
The oncology pipeline educational resources microsite provides unbranded educational resources on Bayer’s various pipeline oncogenic targets and a number of tumour types/disease states of focus that are available to view and download for your own use.
Mechanism of Disease Videos
A series of educational videos providing detailed visual demonstration of key disease pathways, oncogenic targets, and treatment modalities under investigation.
ESMO Content supported by this sponsor
The sponsor did not influence the content provided here
Oncology in Practice
Management of drug-drug interactions with kinase inhibitors
A comprehensive resource that reviews the clinically relevant drug-drug interactions with kinase inhibitors, explores the mechanism of each type of interaction, and provides specific recommendations to guide physicians and clinical pharmacists in daily clinical practice
Management of skin toxicities from multikinase inhibitor therapies
Information, treatment algorithms and educational materials on the management of dermatological side effects associated with multikinase inhibitors, provided in two sections specifically tailored to healthcare professionals or patients and their caregivers
Targeting NTRK Gene Fusions
Two modules that offer comprehensive information on TRK fusion cancer, including an overview of how testing for NTRK gene fusions across multiple tumour types allows for the identification of patients who may benefit from TRK inhibitor therapy
ESMO initiatives supported by this sponsor
The sponsor did not influence the content of these initiatives
Expert video reports: Precision Medicine
A series of experts video reports provide you with the opportunity to learn about the most recent, exciting advancements in precision medicine directly from top-tier oncologists, including innovative therapeutic approaches, key clinical trial results, diagnostic strategies and epidemiological overviews
ESMO advanced courses
These include state of the art lectures, workshops and interactive discussion seminars, and are suitable for experienced oncologists and other specialists complementing the topics covered in the Preceptorship Programme. Each course is accredited with ESMO-MORA CME points (8–12)
Content donated by this sponsor
Medscape educational programmes
Medscape provides accredited independent education activities that have been developed by a dedicated team of scientific directors working in cooperation with leading faculty from major academic institutions. The following activities are supported by Independent Educational Grants from Bayer. Bayer have not influenced the content of these activities
Prostate Cancer Clinic: Multidisciplinary Team Approach to Oral Therapies
An interprofessional panel discuss current and emerging approaches with oral androgen therapies in the management of locally advanced or metastatic prostate cancer and collaborative strategies to implement and monitor therapy
- Prostate Cancer Clinic: Multidisciplinary Team Approach to Oral Therapies
PeerVoice educational programmes
PeerVoice develop independent medical education activities designed to help physicians acquire new clinical skills, test their knowledge, and improve their practice of medicine. The following activities are supported by an Unrestricted Educational Grant from Bayer HealthCare Pharmaceuticals Inc. Bayer has had no involvement in the selection of the speakers, the development of the activities, the agendas, or the materials
Raising the Caliber of Non-Metastatic CRPC Care: Introducing Quality of Life into the Equation
Two video presentations, with supporting resources, examine why quality of life should be a factor when considering treatment strategies for patients with non-metastatic castrate resistant prostate cancer
Defining a Patient-Centred Approach to Non-Metastatic Castration-Resistant Prostate Cancer
Prostate cancer experts analyse the evidence that supports treating non-metastatic castrate resistant prostate cancer and explore strategies to optimise patients’ treatment journeys and their quality of life
Changing Strategies for Changing Times: Optimising Use of Targeted Alpha Therapies for Advanced Prostate Cancer
A panel discussion with prostate cancer experts who review the therapeutic landscape in metastatic castrate resistant prostate cancer and strategies to optimise the use of targeted alpha therapies
- Raising the Caliber of Non-Metastatic CRPC Care: Introducing Quality of Life into the Equation
Industry-sponsored satellite symposia
Precision oncology: Focus on TRK fusion cancer – Molecular Analysis for Personalised Therapy Congress 2019
A Bayer-sponsored satellite symposium entitled ‘Precision oncology: Focus on TRK fusion cancer’, was presented at the Molecular Analysis for Personalised Therapy Congress 2019 in London, UK. Hear Professor Philip Quirke and Professor Fernando López-Ríos examine the latest developments with TRK inhibition in TRK fusion cancer and discuss how NTRK gene fusion detection algorithms can be interpreted and applied in practice.
Targeted treatment in paediatric oncology: Management of TRK fusion cancer – International Society of Paediatric Oncology Congress 2019
A Bayer-sponsored satellite symposium entitled ‘Targeted treatment in paediatric oncology: Management of TRK fusion cancer’, was presented at the 2019 International Society of Paediatric Oncology congress in Lyon, France. Hear Professor Gilles Vassal and Professor Stefan Pfister review NTRK gene fusion testing and TRK inhibitor therapy in TRK fusion paediatric cancer.
Genomic profiling for driver mutations in cancer: NTRK gene fusions – European Congress of Pathology 2019
gene fusions’, was presented at the 2019 European Congress of Pathology in Nice, France. Hear Professor Reinhard Büttner and Professor Giuseppe Viale explore novel genetic markers for cancer and methods for driver mutation detection, specifically that of NTRK gene fusions in TRK fusion cancer.
TRK fusion lung cancer: A new precision oncology approach – European Lung Cancer Congress 2019
A Bayer-sponsored satellite symposium entitled ‘TRK fusion lung cancer: A new precision oncology approach’, was presented at the European Lung Cancer Congress 2019 in Geneva, Switzerland. Hear Professor Lukas Bubendorf and Dr Alexander Drilon explore the role of TRK fusion proteins as primary oncogenic drivers in TRK fusion lung cancer.
A selection of images and infographics that illustrate key concepts of tumour pathophysiology and management strategies, which you can download to enhance your presentations and educational sessions
ESMO only accepts content from third parties after careful evaluation of its educational and scientific relevance to the ESMO target audience. Eligible material should meet the essential criterion of non-promotional intent. Such material may be published in other resources, but the content donor has given permission to ESMO for use in OncologyPRO.